Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Trientine-induced neurological deterioration in a patient with Wilson's disease.

Kim B, Chung SJ, Shin HW.

J Clin Neurosci. 2013 Apr;20(4):606-8. doi: 10.1016/j.jocn.2012.02.041. Epub 2012 Dec 27.

PMID:
23274038
[PubMed - indexed for MEDLINE]
2.

[Wilson's disease with severe neurological manifestations: response to trientine plus zinc therapy].

Serra B, Primo J, García M, Amorós I, Aragó M, Merino C.

Gastroenterol Hepatol. 2004 May;27(5):307-10. Spanish.

PMID:
15117609
[PubMed - indexed for MEDLINE]
3.

Practical recommendations and new therapies for Wilson's disease.

Brewer GJ.

Drugs. 1995 Aug;50(2):240-9. Review.

PMID:
8521757
[PubMed - indexed for MEDLINE]
4.

Recovery after copper-deficiency myeloneuropathy in Wilson's disease.

Teodoro T, Neutel D, Lobo P, Geraldo AF, Conceição I, Rosa MM, Albuquerque L, Ferreira JJ.

J Neurol. 2013 Jul;260(7):1917-8. doi: 10.1007/s00415-013-6963-6. Epub 2013 May 28. No abstract available.

PMID:
23712800
[PubMed - indexed for MEDLINE]
5.

Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.

Morita J, Yoshino M, Watari H, Yoshida I, Motohiro T, Yamashita F, Okano Y, Hashimoto T.

Dev Pharmacol Ther. 1992;19(1):6-9.

PMID:
1307347
[PubMed - indexed for MEDLINE]
6.

Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.

Brewer GJ.

CNS Drugs. 2005;19(3):185-92. Review.

PMID:
15740174
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety of oral chelators in treatment of patients with Wilson disease.

Weiss KH, Thurik F, Gotthardt DN, Schäfer M, Teufel U, Wiegand F, Merle U, Ferenci-Foerster D, Maieron A, Stauber R, Zoller H, Schmidt HH, Reuner U, Hefter H, Trocello JM, Houwen RH, Ferenci P, Stremmel W; EUROWILSON Consortium.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1028-35.e1-2. doi: 10.1016/j.cgh.2013.03.012. Epub 2013 Mar 28.

PMID:
23542331
[PubMed - indexed for MEDLINE]
8.

Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.

Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT.

Transl Res. 2009 Aug;154(2):70-7. doi: 10.1016/j.trsl.2009.05.002. Epub 2009 Jun 6.

PMID:
19595438
[PubMed - indexed for MEDLINE]
9.

[A study of trientine therapy in Wilson's disease with neurological symptoms].

Suda M, Kubota J, Yamaguchi Y, Fujioka Y, Saito Y, Aoki T.

No To Hattatsu. 1993 Sep;25(5):429-34. Japanese.

PMID:
8398232
[PubMed - indexed for MEDLINE]
10.

Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.

Ping CC, Hassan Y, Aziz NA, Ghazali R, Awaisu A.

J Clin Pharm Ther. 2007 Feb;32(1):101-7.

PMID:
17286794
[PubMed - indexed for MEDLINE]
11.

Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.

Lozano Herrero J, Muñoz Bertrán E, Ortega González I, Gómez Espín R, López Espín MI.

Gastroenterol Hepatol. 2012 Dec;35(10):704-7. doi: 10.1016/j.gastrohep.2012.03.008. Epub 2012 May 18.

PMID:
22609346
[PubMed - indexed for MEDLINE]
12.

Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.

Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J.

Arch Neurol. 2006 Apr;63(4):521-7.

PMID:
16606763
[PubMed - indexed for MEDLINE]
13.

Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).

Dahlman T, Hartvig P, Löfholm M, Nordlinder H, Lööf L, Westermark K.

QJM. 1995 Sep;88(9):609-16.

PMID:
7583074
[PubMed - indexed for MEDLINE]
14.

The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.

Purchase R.

Sci Prog. 2013;96(Pt 1):19-32. Review.

PMID:
23738435
[PubMed - indexed for MEDLINE]
15.

Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?

Schilsky ML.

Curr Gastroenterol Rep. 2001 Feb;3(1):54-9. Review.

PMID:
11177695
[PubMed - indexed for MEDLINE]
16.

Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc.

Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ.

J Lab Clin Med. 2003 Dec;142(6):385-90.

PMID:
14713890
[PubMed - indexed for MEDLINE]
17.

Recognition and treatment of neurologic Wilson's disease.

Lorincz MT.

Semin Neurol. 2012 Nov;32(5):538-43. doi: 10.1055/s-0033-1334476. Epub 2013 May 15. Review.

PMID:
23677665
[PubMed - indexed for MEDLINE]
18.

Wilson's disease--treatment of psychiatric manifestations in pregnancy.

Rich AM, Lajoie TM.

Psychosomatics. 2012 Mar-Apr;53(2):175-7. doi: 10.1016/j.psym.2012.01.002. No abstract available.

PMID:
22424165
[PubMed - indexed for MEDLINE]
19.

Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.

Merle U, Schaefer M, Ferenci P, Stremmel W.

Gut. 2007 Jan;56(1):115-20. Epub 2006 May 18.

PMID:
16709660
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Acquired sideroblastic anaemia induced by a copper-chelating agent.

Perry AR, Pagliuca A, Fitzsimons EJ, Mufti GJ, Williams R.

Int J Hematol. 1996 Jul;64(1):69-72.

PMID:
8757970
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk